Academia
New real-world studies from Scotland and England shows that Omicron does not lead to as much hospitalization as Delta. This is consistent with the latest reports from South Africa that say Omicron causes milder disease.
Aduhelm was approved by the U.S. FDA for its ability to clear beta-amyloid. Researchers at Emory investigated the use of an FDA-approved ADHD medication on patients with mild Alzheimer’s symptoms and found it appeared to reduce levels of tau.
Here’s a look at 10 of the more compelling research stories of the year.
The findings may have far-reaching consequences for any COVID-19 vaccines in development that are based upon targeting the well-conserved SARS-CoV-2 nucleocapsid (N-) protein.
With the holidays around the corner and people expected to gather, public health officials have expressed concerns over a possible increase in COVID-19 cases, particularly with the highly infectious Omicron variant on the rise.
Arc begins its mission with $650 million in donations from donors. This funding will sustain the scientists and their researchers over renewable eight-year terms.
A recent study identified a hormone that may drive both type 1 and type 2 diabetes. For that and more research stories, read on.
Deaths from drug overdoses have been on an upward trajectory for years, but have experienced a notable increase since the early days of the COVID-19 pandemic.
Now, researchers are on the threshold of great changes that have the potential to transform non-curable diseases into those that can be cured.
Cancer cells, because of their high metabolism and rapid growth, use up a lot of energy, which is supplied in the body by glucose, or blood sugar.
PRESS RELEASES